According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities ...

The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.

The company said the investment is in response not only to customer demand and a belief in the value of US-based innovation, but also because of the trend toward US onshoring brought about by new ...

Poor API quality may often lead to delays in production and a shortage of supply.

The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy ...

Pharmaceutical Technology is the independent source for information, insight, and analysis on bio/pharmaceutical formulation, development, and manufacturing.

The API is, one might say, the most important element in a pharmaceutical product. Poor-quality APIs that do not meet potency ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about how geopolitical instability in Europe, and beyond, has impacted the bio/pharmaceutical supply chain.

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.